Global IVD Market Overview

The IVD market encompasses all tests conducted on biological samples (blood, urine, tissue, cerebrospinal fluid) outside the body to detect disease, monitor treatment, or screen populations. The major IVD categories by value are: immunoassay (the largest category — measuring proteins, hormones, drugs, and infectious disease markers); clinical chemistry (glucose, electrolytes, liver and kidney function, lipids); haematology (complete blood count, coagulation); molecular diagnostics (PCR, NGS, NAAT — the fastest-growing category); point-of-care testing (portable, near-patient devices); histopathology and digital pathology; and blood banking and transfusion medicine. The five dominant IVD manufacturers globally — Roche Diagnostics, Abbott, Siemens Healthineers, Becton Dickinson, and bioMérieux — collectively hold approximately 65% of market revenue. The remaining 35% is served by hundreds of specialist and regional manufacturers — the space where Turkish manufacturers compete.

IVDR: Threat and Opportunity Simultaneously

EU IVDR (Regulation 2017/746) — which replaced the IVDD — has fundamentally changed the European IVD regulatory landscape. Under IVDR: the vast majority of IVDs previously self-declared as Class A moved to Class B, C, or D (requiring Notified Body involvement); clinical performance evidence requirements are substantially higher; EUDAMED registration is mandatory; and the transition deadlines (Class C: May 2026; Class B: May 2027) are forcing manufacturers to either achieve IVDR compliance or exit the EU market. For Turkish IVD manufacturers, this is simultaneously a threat (IVDR compliance requires significant investment) and a competitive opportunity (EU and Eastern European IVD manufacturers who cannot afford or fail to achieve IVDR compliance are exiting the market — creating distributor vacancies and procurement gaps that well-prepared Turkish manufacturers can fill). The Turkish IVD manufacturers who invest in IVDR Notified Body relationships, clinical performance studies, and EUDAMED registration will emerge from the transition with stronger EU market positions than those who do not.

Clinical Chemistry: Turkey's Strongest IVD Position

Turkish clinical chemistry reagent manufacturers have established the country's strongest IVD export positions — producing CE-certified reagents for clinical chemistry analysers (glucose, creatinine, bilirubin, liver enzymes, cholesterol profiles, electrolytes) that compete with Roche and Abbott in price while meeting comparable analytical performance standards. Turkish clinical chemistry reagents are exported primarily to Middle Eastern (Gulf states, Egypt, Iran), CIS (Kazakhstan, Russia, Uzbekistan), and Eastern European (Romania, Bulgaria) markets. The analyser/reagent tie-in model — where Turkish manufacturers supply open-system reagents compatible with multiple analyser platforms — is the primary commercial structure, avoiding the need to manufacture analysers while enabling reagent volume sales. IVDR clinical performance data (sensitivity, specificity, accuracy compared to reference methods) is the key competitive documentation for clinical chemistry reagents.

Rapid Test Platforms: COVID-19 Legacy and Enduring Growth

COVID-19 rapid antigen tests demonstrated the global scalability of lateral flow assay (LFA) technology — and this demonstration effect has created sustained demand for rapid test development across multiple infectious disease categories. Turkish manufacturers with lateral flow assay manufacturing capability are positioned in a category with strong enduring growth: respiratory viral tests (influenza A/B, RSV, COVID-19 combination panels); sexually transmitted infection rapid tests (HIV, syphilis, hepatitis B and C); malaria and dengue rapid tests for tropical disease markets; tropical disease panels for African and Southeast Asian markets; and companion diagnostics for antibiotic stewardship (CRP, procalcitonin). The IVDR regulatory pathway for most rapid tests is Class C (Notified Body CE marking required) — which raises the entry barrier but also rewards manufacturers who invest in proper clinical validation with more defensible market positions.

Molecular Diagnostics: The High-Ceiling Opportunity

Molecular diagnostics — PCR, isothermal amplification (LAMP), and emerging NGS-based tests — represent the highest-value and highest-growth IVD category. The COVID-19 pandemic accelerated molecular diagnostic capacity investment globally, creating instrument infrastructure (PCR machines, real-time PCR systems) in hospital laboratories that are now seeking compatible reagent and test solutions. Turkish manufacturers with molecular biology expertise can develop CE-IVD reagent kits for: respiratory viral detection panels (flu/RSV/COVID multiplex PCR); sexually transmitted infection molecular tests; antimicrobial resistance gene detection; and oncology companion diagnostics (mutation detection in tumour DNA). Molecular IVD development requires significant R&D investment and IVDR clinical performance validation — but the market returns justify the investment for manufacturers with genuine molecular biology capability. Several Turkish university biotechnology spinouts and established IVD companies are active in this space.

Distribution Strategy for Turkish IVD Exporters

IVD distribution is categorically different from medical device distribution — IVD buyers are laboratory managers and clinical biochemists, not hospital procurement managers or surgeons. IVD distributors typically have: laboratory equipment sales capability (placing analysers as placement instruments or capital sales); reagent logistics capability (temperature-controlled storage, batch number tracking, expiry date management); laboratory service and calibration capability (reagent optimisation, QC troubleshooting); and established relationships with hospital laboratory managers. Turkish IVD manufacturers should target IVD-specialist distributors rather than general medical device distributors — a distributor who sells surgical instruments and hospital furniture alongside IVD reagents typically lacks the laboratory-specific technical relationships and knowledge that drive IVD adoption.

Conclusion

The global IVD market's scale, growth trajectory, and technology momentum make it one of the most rewarding segments for Turkish manufacturers who invest in the regulatory compliance, clinical performance documentation, and laboratory-specialist distribution infrastructure that IVD market success requires. The IVDR transition — while demanding — is creating competitive opportunity for properly prepared Turkish IVD manufacturers in European and regulated global markets. Turkish IVD manufacturers who navigate this transition successfully will emerge with stronger, more defensible market positions than they held before it began.